Cardio Diagnostics Holdings (CDIO) Receivables (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Receivables of $4274.0 for Q1 2026, down 47.4% sequentially from $8126.0 in Q4 2025, and down 55.26% YoY from $9552.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Receivables (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Receivables for 5 years, with the latest figure at $4274.0 in Q1 2026.
- Quarterly Receivables fell 55.26% year-over-year to $4274.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4274.0 (down 55.26% YoY) and the FY2025 annual result came in at $8126.0, down 56.34% from the prior year.
- Receivables eased to $4274.0 in Q1 2026 per CDIO's latest filing, from $8126.0 in the prior quarter.
- Over five years, Receivables peaked at $18988.0 in Q1 2024 and troughed at $350.0 in Q3 2023.
- A 4-year average of $9306.7 and a median of $8839.0 in 2025 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables jumped 3928.57% in 2024, then sank 56.34% in 2025.
- Over 4 years, Receivables stood at $4960.0 in 2023, then surged by 275.24% to $18612.0 in 2024, then tumbled by 56.34% to $8126.0 in 2025, then plunged by 47.4% to $4274.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $4274.0, $8126.0, and $11221.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.14 Mn | 554,201.32 | - | 3,905.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,905.00 |
| Mar 31, 2026 | 4,274.00 |
| Dec 31, 2025 | 8,126.00 |
| Sep 30, 2025 | 11,221.00 |
| Jun 30, 2025 | 12,927.00 |
| Mar 31, 2025 | 9,552.00 |
| Dec 31, 2024 | 18,612.00 |
| Sep 30, 2024 | 14,100.00 |
| Jun 30, 2024 | 7,520.00 |
| Mar 31, 2024 | 18,988.00 |
| Dec 31, 2023 | 4,960.00 |
| Sep 30, 2023 | 350.00 |
| Jun 30, 2023 | 1,050.00 |
| Dec 31, 2021 | 901.00 |